Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Moodys
Fuji
Deloitte
Covington
Julphar
Healthtrust
Accenture
Cerilliant

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VARDENAFIL HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Vardenafil Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00377793 Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II Completed Bayer Phase 4 This trial is to provide additional important information on the impact of the treatment of the man its ED with vardenafil on partnership. This study is being run at up to 50 study centers in Europe and South Africa to evaluate the use of vardenafil in adult men with erectile dysfunction (often called impotence), and their female partner's sexual quality of life. Many men experience occasional erectile problems during their lives. However, when this becomes a continued problem, it can affect both the man and his female partner. The causes of erectile dysfunction are varied and may be due to physiological or emotional reasons. This study is designed to 1) study the effectiveness and safety of vardenafil, and 2) show whether treating a man its erectile dysfunction with vardenafil will improve his female partner its sexual quality of life. The second part (week 12) of the study (Educational program) a subgroup of subjects/couples, approximately 50% of the randomized subjects, will receive an educational program concerning ED in the from of a DVD.
NCT00379756 A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia Completed GlaxoSmithKline Phase 4 This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months.
NCT00448123 The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients Completed William Beaumont Hospitals N/A To determine if emergency department patients with acute ureteral colic pain due to a ureteral stone who are treated with tamsulosin, versus placebo, will experience a shorter time to passage of their stone or resolution of their pain. A secondary study objective will be to determine if there is a relationship between response to tamsulosin and stone size or position in the ureter.
NCT00448123 The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients Completed Robert Swor N/A To determine if emergency department patients with acute ureteral colic pain due to a ureteral stone who are treated with tamsulosin, versus placebo, will experience a shorter time to passage of their stone or resolution of their pain. A secondary study objective will be to determine if there is a relationship between response to tamsulosin and stone size or position in the ureter.
NCT00461123 Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Completed Bayer Phase 2 The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. In the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of hemoglobin in the respective tissue. Therefore, increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of the laser application and consequently shortening of the required duration of laser application.
NCT00461565 FDA Phase IV - Commitment - Retinal Function Study Completed GlaxoSmithKline Phase 4 Vardenafil (Levitra) and Sildenafil (Viagra) are drugs that are marketed for use in patients with erectile dysfunction. The purpose of this study is to find out if there are any changes in the eye after taking at least 15 doses of Vardenafil and after two doses of Sildenafil. This is a double-blind study, which means that neither you nor the study doctor will know which treatment you are receiving. If you qualify for the study, you will receive:- Vardenafil 20 mg twice per week (Monday and Thursday) for a maximum of 8 weeks. There will be two times when this occurs during the study.- Sildenafil 200 mg/day for two days. There will be two times when this occurs during the study. - Placebo (a pill that looks like vardenafil or sildenafil but has no active ingredient).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vardenafil Hydrochloride

Condition Name

Condition Name for Vardenafil Hydrochloride
Intervention Trials
Erectile Dysfunction 53
Sexual Dysfunction 3
Impotence 2
Endothelial Dysfunction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vardenafil Hydrochloride
Intervention Trials
Erectile Dysfunction 58
Hypertension 6
Spinal Cord Injuries 4
Prostatic Hyperplasia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vardenafil Hydrochloride

Trials by Country

Trials by Country for Vardenafil Hydrochloride
Location Trials
United States 162
Germany 94
Spain 36
United Kingdom 32
Canada 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vardenafil Hydrochloride
Location Trials
Florida 11
California 11
New York 11
North Carolina 9
Connecticut 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vardenafil Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Vardenafil Hydrochloride
Clinical Trial Phase Trials
Phase 4 29
Phase 3 24
Phase 2/Phase 3 2
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vardenafil Hydrochloride
Clinical Trial Phase Trials
Completed 63
Unknown status 7
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vardenafil Hydrochloride

Sponsor Name

Sponsor Name for Vardenafil Hydrochloride
Sponsor Trials
Bayer 50
GlaxoSmithKline 19
Schering-Plough 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vardenafil Hydrochloride
Sponsor Trials
Industry 82
Other 26
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Moodys
Chubb
Fish and Richardson
Covington
Boehringer Ingelheim
Dow
Queensland Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.